期刊
JOURNAL OF CLINICAL MEDICINE
卷 10, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/jcm10194558
关键词
extended-release naltrexone; opioid dependence; mental distress; impulsivity
资金
- Research Council of Norway [269864]
- South-Eastern Norway Regional Health Authority [2019105]
Patients with substance use disorder have higher levels of impulsivity, hyperactivity, and inattention (IHI) compared to the general population. However, the prevalence of such symptoms in patients seeking treatment with an opioid antagonist like extended-release naltrexone (XR-NTX) is unknown. Screening for IHI and mental distress in opioid maintenance treatment and XR-NTX could improve care quality and help tailor interventions for patients with high levels of IHI to prevent treatment discontinuation.
The level of impulsivity, hyperactivity, and inattention (IHI) is higher among patients with substance use disorder (SUD) than in the general population. However, the prevalence of such symptoms in patients seeking treatment with an opioid antagonist, such as extended-release naltrexone (XR-NTX), is unknown. We screened 162 patients with opioid use disorder (OUD) seeking treatment with XR-NTX in Norway using the Adult ADHD Self-Report Scale (ASRS) to estimate the prevalence of IHI alongside an assessment of mental and physical health and substance use. Sixty-six patients scored above the clinical cut-off on the ASRS. Higher levels of IHI were significantly associated with a longer history of frequent amphetamine use, current alcohol use, and greater mental distress. Mental distress was the strongest factor associated with higher levels of IHI. The introduction of screening for IHI and mental distress in opioid maintenance treatment and XR-NTX would likely improve the quality of care and enable clinicians to tailor interventions to the needs of patients with high levels of IHI to prevent treatment discontinuation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据